Efficacy, Safety and Tolerability of Pioglitazone-Azilsartan in Subjects With Type 2 Diabetes Mellitus

PHASE3TerminatedINTERVENTIONAL
Enrollment

96

Participants

Timeline

Start Date

June 30, 2006

Primary Completion Date

May 31, 2007

Study Completion Date

May 31, 2007

Conditions
Type 2 Diabetes
Interventions
DRUG

Pioglitazone and Azilsartan

Pioglitazone 45 mg and Azilsartan 20 mg combination tablets, orally, once daily for up to 24 weeks.

DRUG

Pioglitazone and Azilsartan

Pioglitazone 45 mg and Azilsartan 40 mg combination tablets, orally, once daily for up to 24 weeks.

DRUG

Pioglitazone

Pioglitazone 45 mg, tablets, orally, once daily for up to 24 weeks.

Trial Locations (73)

Unknown

Huntsville

Tallassee

Little Rock

Auburn

Bakersfield

Buena Park

Chula Vista

Huntington Park

Los Gatos

Norwalk

Orangevale

Sacramento

Stockton

Deerfield Beach

Hialeah

Hollywood

Jacksonville

Kissimmee

Marianna

Melbourne

Miami

Pembroke Pines

Winter Haven

Augusta

Dunwoody

Chicago

Bloomington

Evansville

Shawnee Mission

Prince Frederick

Livonia

Saint Clair Shores

Las Vegas

Trenton

Albany

Johnson City

Staten Island

Charlotte

Salisbury

Winston-Salem

Marion

Oklahoma City

Buckingham

Jeannette

Mt. Pleasant

Simpsonville

Bristol

New Tazewell

Dallas

El Paso

Euless

Fort Worth

Houston

McKinney

Midland

North Richland Hills

San Antonio

Falls Church

Virginia Beach

Buenos Aires

Córdoba

Santa Fe

Santiago

Temuco

León

Zapopan

Monterrey

Guadalajara

Mexico City

Arequipa

Lambayeque

Lima

Trujillo

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Takeda

INDUSTRY